Merck/Kyorin Phase III Dual PPAR Agonist On First-In-Class Path For Diabetes

Merck/Kyorin's dual peroxisome proliferator-activated receptor agonist MK-0767, a new antidiabetic in Phase III, appears to be winning the development race for first market entrant in its class

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet